Cell Therapy for Heart Failure: Latest Trials & Progress
- New approaches to treating heart failure through cell therapy are under inquiry, following decades of research that led to current accepted therapies.
- A review of 20 years of clinical trials on cell-based therapies for heart failure indicates that while no treatment has yet gained approval,the therapies have proven safe,with some...
- Jianyi "Jay" Zhang, professor and chair of biomedical engineering at the University of Alabama at Birmingham (UAB), and his colleagues published their review in Nature Reviews Cardiology.
Cell therapy for heart failure shows immense promise, but faces challenges detailed in a new review of clinical trials. Discover how researchers are exploring cutting-edge approaches to cardiac repair with primary_keyword cell-based therapies, aiming to combat the devastating effects of heart failure. This thorough analysis examines both the successes and failures of the last two decades, highlighting the need for rigorous trial design and the potential of novel cell types and delivery methods.While no treatments have yet gained approval, these secondary_keyword therapies have proven safe, offering hope to millions. Through expert insights and a look at current research, News Directory 3 delivers crucial facts on the status and the future of cell therapy. Discover what’s next in the ongoing quest to improve heart health.
Cell Therapy for Heart Failure: Trials Show Promise, Face Hurdles
New approaches to treating heart failure through cell therapy are under inquiry, following decades of research that led to current accepted therapies. These efforts focus on repairing scar tissue in damaged hearts after a heart attack, but experts caution that developing effective clinical treatments will require time.
A review of 20 years of clinical trials on cell-based therapies for heart failure indicates that while no treatment has yet gained approval,the therapies have proven safe,with some demonstrating beneficial effects. The research emphasizes that optimizing existing heart failure treatments,such as implantable cardioverter-defibrillators and guideline-directed medical therapy,took nearly 40 years.
Jianyi “Jay” Zhang, professor and chair of biomedical engineering at the University of Alabama at Birmingham (UAB), and his colleagues published their review in Nature Reviews Cardiology. They argue that the history of developing life-saving therapies for heart failure offers hope for cell therapy’s potential.
Heart failure accounts for 13% of global deaths, with half of patients dying within five years. Coronary artery blockage, leading to the death of heart muscle cells, is a primary cause. Scar tissue replaces damaged muscle, reducing the heart’s pumping ability and increasing the risk of arrhythmias and end-stage heart failure.
Since human heart muscle cells lose their ability to divide shortly after birth, damaged hearts cannot regenerate. Early cell therapies aimed to replace damaged cells with new ones in the scar tissue.
The review in Nature Reviews Cardiology details the progress,obstacles,and skepticism surrounding implantable cardioverter-defibrillators and guideline-directed medical therapy. It also examines 13 completed and 10 ongoing clinical trials to assess the safety and efficacy of cell- and cell product-based therapy approaches.
Zhang noted that while past trials suggest that even a single dose of cell products can benefit heart failure patients, current trials explore new avenues.
- New cell types,including pluripotent stem cell-derived cardiomyocytes and umbilical cord-derived mesenchymal stem cells,are being tested.
- Repeated intravenous injections are being explored as a noninvasive delivery method.
- New cell products, such as engineered epicardial cardiomyocyte patches, are in progress.
- Novel cell-free products, like extracellular vesicle-enriched secretomes, are also under investigation.
“The results of these trials will continue to define and refine our understanding of cell and cell product therapy as a novel addition in the treatment of patients with heart failure,” Zhang said.
The review addresses criticisms of cell therapy research,including concerns about the use of public funding for underpowered trials and modest improvements in cardiac function. Zhang stressed that future trials must be adequately powered and rigorously designed to address these concerns.
“These criticisms must be addressed in future trials that are adequately powered and rigorously designed to ensure continued progress of the field,” Zhang said.
Despite the challenges, Zhang remains optimistic about the future of cell therapy. He believes that current research will lead to clinical applications, noting that cell therapy has emerged as a promising approach for cardiac repair and regeneration over the past 20 years.
Steven M. Pogwizd of UAB, Keiichi Fukuda of Keio University, Wolfram-Hubertus Zimmermann of Georg-August-University, Chengming Fan of Central South University, Joshua M. Hare of the University of Miami, Roberto Bolli of the University of Louisville, and Philippe menasché of Université de Paris co-authored the review.
The National Institutes of Health provided funding for the research through grant HL134764.
What’s next
Researchers plan to continue refining cell therapy approaches, addressing criticisms through improved trial design and exploring new cell types and delivery methods to enhance cardiac repair and regeneration for heart failure patients.